GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Belluscura PLC (FRA:9VQ) » Definitions » Notes Receivable

Belluscura (FRA:9VQ) Notes Receivable : €0.00 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Belluscura Notes Receivable?

Belluscura's Notes Receivable for the quarter that ended in Jun. 2023 was €0.00 Mil.


Belluscura Notes Receivable Historical Data

The historical data trend for Belluscura's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belluscura Notes Receivable Chart

Belluscura Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Notes Receivable
- - - - -

Belluscura Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Notes Receivable Get a 7-Day Free Trial Premium Member Only - - - - -

Belluscura Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Belluscura Notes Receivable Related Terms

Thank you for viewing the detailed overview of Belluscura's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Belluscura (FRA:9VQ) Business Description

Traded in Other Exchanges
Address
15 Fetter Lane, Holborn, London, GBR, EC4A 1BW
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.

Belluscura (FRA:9VQ) Headlines

No Headlines